A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Range Finding Study to Evaluate the Efficacy of Oglemilast in the Treatment of Stable Mild to Moderate Persistent Asthma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Oglemilast (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 25 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2009 Planned end date changed from Sep 2009 to Jan 2010 as reported by ClinicalTrials.gov.
- 10 Mar 2009 Planned number of patients changed from 230 to 282 based on information from ClinicalTrials.gov.